Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12890997 | 0.80 | CYP3A4 (0.37) | CYP3A4MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL12891001 | 0.77 | KCNH2 (0.35) | CYP3A4MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL10285896 | 0.76 | SMN1; SMN2 (0.43) | CYP3A4MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL19370115 | 0.74 | CA1 (0.40) | CYP3A4MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL2540881 | 0.74 | MEN1 (0.38) | CYP3A4MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL12503454 | 0.72 | KMT2A (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2CA1 | |
| SCHEMBL10981320 | 0.69 | MEN1 (0.39) | CYP3A4MEN1CYP1A2KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3710557 | 0.69 | CA1 (0.37) | CYP3A4MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL18427626 | 0.67 | CYP3A4 (0.55) | CYP3A4MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL1272580 | 0.67 | CA1 (0.42) | CYP3A4MEN1CYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | CYP3A4 2595/4885MEN1 977/4885CYP1A2 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.